<DOC>
	<DOCNO>NCT00028405</DOCNO>
	<brief_summary>This multi-center photodynamic therapy study plan treat patient large tumor superficial location , sarcoma , tumor oral/oro-pharyngeal cavity , tumor extensive pelvic involvement , liver metastasis . The treatment limit patient fail respond currently approve method treatment . The study involve single , intravenous administration investigational drug , LS11 ( previously study approximately 80 cancer patient ) placement novel , flexible light delivery catheter inside tumor minor surgical procedure . The activation LS11 light delivery catheter period 1-24 hr may result destruction tumor tissue .</brief_summary>
	<brief_title>Photodynamic Therapy System Patients With Refractory/Unresponsive Solid Tumors</brief_title>
	<detailed_description>In Phase I photodynamic therapy study , patient undergo standard CT scan determine suitability treatment . In patient qualify entry criterion , light delivery catheter directly insert tumor minor surgical procedure . The patient injected photosensitive drug , LS11 . One hour follow drug injection , light energy deliver light delivery catheter period 1-24 hour . The duration light treatment give patient may base various factor include give patient enters study . Following delivery light energy , light delivery catheter remove tumor . The insertion removal catheter carry guidance CT scan . The patient ask take precaution external light exposure period time . The patient undergo CT scan test day 7 , 14 42 evaluate safety treatment , tumor cell death treatment response . Blood sample take different time point examine clearance drug body .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Pelvic Neoplasms</mesh_term>
	<mesh_term>Mouth Neoplasms</mesh_term>
	<mesh_term>Talaporfin</mesh_term>
	<criteria>Primary Target tumor accessible percutaneous implantation CT ( ultrasound need ) guidance superficial location , sarcoma , tumor oral/oropharyngeal cavity , tumor extensive pelvic involvement , liver metastasis . Patient fail prior surgery chemotherapy radiation therapy tumor refractory . Tumor mass immediately adjacent , directly invade major vessel hollow viscus tumor necrosis could result hemorrhage perforation . Patient receive prior chemotherapy least 4 week patient recover toxicity . Patient ECOG performance status 03 ( Karnofsky 30 high ) . If patient receive radiotherapy site disease one plan insertion light delivery catheter , patient must current local systemic toxicity prior radiation . Patient recover previous surgery judgment Principal Investigator . Patient treat biologics ( exclude hormone ) least 4 week prior screen patient recover toxicity . Age 18 old . Minimum life expectancy 12 week . Ability provide inform consent . All tumor must : minimum dimension exceed 4 x 2.8 cm ; shape location midpoint light delivery catheter great 2.0 cm structure , damage PDT treatment , would result pain injury patient . History cardiovascular abnormality , include , myocardial infarction last 6 month , arrhythmia , uncontrolled congestive heart failure ; History ongoing , significant active medical illness might create risk patient , opinion Investigator ; History know suspected porphyria ; Concomitant use drug know produce skin photosensitivity ; Women pregnant lactating ; Hematopoietic abnormality baseline examination , evidence follow laboratory value ( US Units ) : Hemoglobin &lt; 10 g/dL ; White blood cell ( WBC ) count &lt; 2500/mm3 ; Neutrophil count &lt; = 1500/uL ; Platelet count &lt; = 100,000/mm3 ; Renal liver function abnormality baseline examination , evidence follow laboratory value ( US Units ) : Serum Creatinine &gt; 2.0 mg/dL ; Total bilirubin &gt; 2.0 mg/dL ; SGOT ( AST ) &gt; 3x ULN ; SGPT ( ALT ) &gt; 3x ULN ; GGT &gt; 3x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>Photodynamic Therapy</keyword>
	<keyword>Bulky Tumor</keyword>
	<keyword>Refractory Tumor</keyword>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Pelvic Tumors</keyword>
	<keyword>Liver Metastasis</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Anal Cancer</keyword>
	<keyword>Oral Cancer</keyword>
	<keyword>Recurrent</keyword>
	<keyword>Lymphadenopathy</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Cervical Cancer</keyword>
</DOC>